Alta Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Alta Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$314K	Hold	407	–	–	0.11%	127
2025 Q4	$314K	Sell	407 -200	-33%	-$136K	0.11%	124
2025 Q3	$341K	Hold	607	–	–	0.1%	159
2025 Q2	$319K	Hold	607	–	–	0.11%	162
2025 Q1	$385K	Buy	607 +250	+70%	+$172K	0.16%	125
2024 Q4	$254K	Buy	357 +57	+19%	+$47.8K	0.16%	122
2024 Q3	$315K	Hold	300	–	–	0.14%	84
2024 Q2	$315K	Hold	300	–	–	0.15%	80
2024 Q1	$289K	Hold	300	–	–	0.14%	88
2023 Q4	$263K	Hold	300	–	–	0.14%	90
2023 Q3	$247K	Hold	300	–	–	0.14%	84
2023 Q2	$216K	Hold	300	–	–	0.12%	100
2023 Q1	$247K	Hold	300	–	–	0.15%	86
2022 Q4	$216K	Hold	300	–	–	0.13%	94
2022 Q3	$207K	Buy	+300	New	+$189K	0.13%	84

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alta Advisers's REGN Position: Q1 2026 in Review

Alta Advisers held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 407 shares worth $314K. The position accounts for 0.11% of the portfolio, ranked #127.

Alta Advisers first reported a position in REGN in Q3 2022 and has held it in 15 quarters since. The position peaked at $385K in Q1 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Alta Advisers held 407 shares of Regeneron Pharmaceuticals worth $314K as of Q1 2026.
Alta Advisers left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.11% of Alta Advisers's portfolio in Q1 2026, its #127 holding.
Alta Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Alta Advisers's Regeneron Pharmaceuticals position peaked at $385K in Q1 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Alta Advisers's 13F filing for Q1 2026, filed 7 May 2026.